UNLIMITED TURBO BEAR - NOVO-NORDISK B | Real-time Euronext Paris 05:59:25 2024-06-04 EDT | ||
| 1.985 EUR | -0.75% |
|
| Current month | -2.20% | ||
| 1 month | -20.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 1.985 | -0.75% |
| 24-06-03 | 2 | -2.20% |
| 24-05-31 | 2.045 | -0.24% |
| 24-05-30 | 2.05 | -1.68% |
| 24-05-29 | 2.085 | +1.71% |
Real-time Euronext Paris
Last update June 04, 2024 at 05:59 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 6B71S | |
| ISIN | DE000SU9LYG8 |
| Date issued | 2024-02-20 |
| Strike | 1,223 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 2.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.815 € |
|---|---|
| Lowest since issue | 1.885 € |
| Spread | 0.01 € |
| Spread % | 0.51% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.3
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- 6B71S Certificat
